The USFDA has issued 8 observations for the drug product facility and API facility at Mandideep. The US drug regulator has inspected company’s Mandideep unit-1 facility during November 14-23, 2022.

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy